MMSET knockdown and knockout reduces tumorigenicity of t(4;14)+ MM xenografts
| Cell line . | Tumor frequency, no. tumors/no. injections* . |
|---|---|
| KMS-11 | |
| Control | 14/14 |
| Knockdown | 2/16† |
| Parental | 8/10 |
| Non-T-KO | 6/9‡ |
| T-KO | 0/14§ |
| NCI-H929 | |
| Control | 4/8¶ |
| Knockdown | 2/8 |
| Cell line . | Tumor frequency, no. tumors/no. injections* . |
|---|---|
| KMS-11 | |
| Control | 14/14 |
| Knockdown | 2/16† |
| Parental | 8/10 |
| Non-T-KO | 6/9‡ |
| T-KO | 0/14§ |
| NCI-H929 | |
| Control | 4/8¶ |
| Knockdown | 2/8 |
Athymic nude mice were injected subcutaneously with 107 KMS-11 cells transduced with empty lentiviral vector or MMSET shRNA lentivirus. In separate experiments, athymic nude mice were injected subcutaneously with parental KMS-11 cells or KMS-11 clones with heterozygous disruption of MMSET (T-KO and non-T-KO). NCI-H929 cells transduced with empty lentiviral vector or MMSET shRNA lentivirus were injected subcutaneously into NOD/SCID mice.
Frequency indicates number of tumors/number of injections at the end of a 5-week observation period.
P < .001 by χ2 versus control.
P = .63 versus parental.
P = .008 versus non-T-KO.
Mean final tumor weight of controls equals 0.755 g. Mean final weight of knockdown tumors equals 0.178 g.